VITAL KSK HOLDINGS,INC.

Government-led healthcare insurance system reforms and drug pricing standard revisions directly affect the Group's business results. In addition to the main revision conducted once every two years, the drug pricing standard is effectively reduced annually through mid-year revisions, and items with expanded market size are also reviewed up to four times per year. Since the upper limit on sales prices of prescription pharmaceuticals, the Group's main products, is regulated by the drug pricing standard, this constitutes a continuing factor pressuring profitability.

Gross profit in the pharmaceutical wholesale business consists of trading margins plus rebates and sales incentives from pharmaceutical manufacturers, which are subject to periodic revision due to changes in manufacturers' policies and sales strategies. There is a risk that changes in manufacturers' pricing policies will directly impact the Group's revenue structure. The Group addresses this by periodically reviewing trading terms with manufacturers and proposing collaborative initiatives.

While the pharmaceutical wholesale industry is shifting toward item-by-item unit pricing transactions, excessive price competition may arise due to competitors' regional strategies and other factors. If price competition intensifies, market prices may decline, forcing the Company to respond with price adjustments; failure to respond could lead to a decrease in the number of items sold. The Group strives to maintain deliveries at appropriate prices in accordance with distribution improvement guidelines.

In the pharmaceutical wholesale industry, there is a practice of delivering products to medical institutions and others before the delivery price is finalized, with price negotiations conducted afterward, and such negotiations may become prolonged. When prolonged, revenue is recognized based on a reasonably estimated expected price, and any divergence from the finally determined price may impact business results. The Group strives to maintain deliveries at appropriate prices in accordance with distribution improvement guidelines.

The Group holds investment securities such as stocks, and impairment processing becomes necessary when market value declines. The policy is to fully impair all securities with a decline rate of 50% or more, and to impair securities with a decline rate of 30% or more but less than 50% that meet certain conditions, after considering the possibility of recovery. Each year, the Board of Directors assesses the rationality of holding each security, maintaining a system whereby only securities recognized as rational to hold are retained.

If unexpected information leakage occurs, it could result in loss of social trust, liability for damages, and suspension of business transactions, potentially affecting business results. As a pharmaceutical wholesaler holding extensive customer information from medical institutions and others, the importance of information management is high. The Group has established a basic policy on personal information protection, an information security policy, and related regulations, and strives to thoroughly educate employees and rigorously protect and manage customer information.

Business activities heavily rely on computer systems and networks, and large-scale system troubles caused by accidents, disasters, malware including ransomware, and other factors could affect business results. Given the nature of the business, which is responsible for the stable supply of pharmaceuticals, system outages would also have a significant impact on business partners. As countermeasures, the Group conducts 24/7/365 status monitoring, centralized management at high-security data centers, installation of emergency power generators, and implementation of redundant network configurations.

If a large-scale natural disaster or accident occurs, it could disrupt business activities and affect business results. To maintain the continued stable supply of pharmaceuticals, the Group has formulated BCPs and disaster response manuals, and has installed emergency power generation equipment and disaster response vehicles at major logistics centers and offices.

As the Group's main business is pharmaceutical wholesaling, it requires the registration or designation of licenses and permits, as well as various approvals, based on the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices and related laws and regulations, and the status of licensing and approval by regulatory authorities could affect business results. If regulatory violations occur or licenses and permits are revoked or suspended, there is a risk of significant disruption to business continuity. The Group strives to comply with laws and regulations by establishing a compliance code and thoroughly educating employees.